WEST Search History

09/865,859

DATE: Tuesday, April 30, 2002

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L1	troglitazone	234	L1
L2	L1 and angiogenesis	11	L2
L3	L2 and inhibition	11	L3
L4	L3 and tumor	10	L4
L5	L3 and cancer	7	L5
L6	L5 and inhibition	7	L6
L7	L4 and inhibition	10	L7
L8	L5 and inhibition	7	L8

END OF SEARCH HISTORY

STN
4/30/02
09/865,853

Welcome to STN International! Enter x:x

LOGINID:ssspta1202sxq

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:23:22 ON 30 APR 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:23:41 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 29 APR 2002 HIGHEST RN 409058-68-0
DICTIONARY FILE UPDATES: 29 APR 2002 HIGHEST RN 409058-68-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s troglitazone
L1 9 TROGLITAZONE

=> d l1 1-9

L1 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 343978-29-0 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-, dihydrate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Troglitazone dihydrate**
MF C24 H27 N O5 S . 2 H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (97322-87-7)



● 2 H_2O

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 189764-85-0 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[[(2R)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-, [S-(R*,S*)]-

OTHER NAMES:
CN **(2R,5S)-Troglitazone**
FS STEREOSEARCH
MF C24 H27 N O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 189764-84-9 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[[(2S)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-, [S-(R*,R*)]-
OTHER NAMES:
CN **(2S,5S)-Troglitazone**
FS STEREOSEARCH
MF C24 H27 N O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2002 ACS

RN 189764-83-8 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[[(2R)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methyl]-, (5R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-, [R-(R*,R*)]-
OTHER NAMES:
CN **(2R,5R)-Troglitazone**
FS STEREOSEARCH
MF C24 H27 N O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 189764-81-6 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[[(2S)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methyl]-, (5R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-, [R-(R*,S*)]-
OTHER NAMES:
CN **(2S,5R)-Troglitazone**
FS STEREOSEARCH
MF C24 H27 N O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 136665-44-6 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)butoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ROY 1358
CN **Troglitazone quinone**
FS 3D CONCORD
MF C24 H27 N O6 S
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1967 TO DATE)

15 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 127040-01-1 REGISTRY
CN .beta.-D-Glucopyranosiduronic acid, 2-[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenoxy]methyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-yl (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ROY 1515
CN **Troglitazone glucuronide**
FS STEREOSEARCH
MF C30 H35 N O11 S
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1967 TO DATE)
10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 107187-86-0 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[[3,4-dihydro-2,5,7,8-tetramethyl-6-(sulfooxy)-2H-1-benzopyran-2-yl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ROY 1357
CN **Troglitazone sulfate**
CN **Troglitazone sulfate ester**
FS 3D CONCORD
MF C24 H27 N O8 S2
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1967 TO DATE)
21 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2002 ACS
RN 97322-87-7 REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 58: PN: WO0148150 SEQID: 73 claimed sequence
CN CI 991
CN CS 045
CN GR 92132X
CN Noscal
CN Rezulin
CN Romglizone
CN **Troglitazone**
FS 3D CONCORD
DR 259223-65-9
MF C24 H27 N O5 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

786 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
792 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.60	18.81

FILE 'CAPLUS' ENTERED AT 14:24:32 ON 30 APR 2002

FILE COVERS 1907 - 30 Apr 2002 VOL 136 ISS 18
FILE LAST UPDATED: 29 Apr 2002 (20020429/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> s l1
L2          795 L1

=> d his

     (FILE 'HOME' ENTERED AT 14:23:22 ON 30 APR 2002)

     FILE 'REGISTRY' ENTERED AT 14:23:41 ON 30 APR 2002
L1            9 S TROGLITAZONE

     FILE 'CAPLUS' ENTERED AT 14:24:32 ON 30 APR 2002
L2          795 S L1

=> s l2 and angiogenesis
         12822 ANGIOGENESIS
L3           10 L2 AND ANGIOGENESIS

=> d 1-10 ibib hitstr abs

L3   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2002:142506  CAPLUS
DOCUMENT NUMBER:          136:177977
TITLE:                    Methods for treating inflammatory diseases using PPAR
                          agonists
INVENTOR(S):              Pershadsingh, Harrihar A.
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 42 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2002013812      A1   20020221      WO 2001-US25668  20010816
         W:  AU, CA, MX, NZ, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
PRIORITY APPLN. INFO.:                US 2000-225907P  P  20000817
                                      US 2000-230509P  P  20000906
IT   97322-87-7, Troglitazone
```

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating inflammatory diseases using PPAR agonists)
RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatol., cardiovascular immunol., neurol., ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addn., methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amt. of pharmacol. compns. comprising a pharmaceutically acceptable carrier, and a PPAR.gamma. agonist which cross-activates PPAR.alpha. or PPAR.delta. or both, or a PPAR.gamma. partial agonist, or a PPAR.gamma./RXR agonist, effective to reverse, slow, stop, or prevent the pathol. inflammatory or degenerative process.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:884254 CAPLUS
DOCUMENT NUMBER: 136:160858
TITLE: Top 200 medicines: can new actions be discovered through computer-aided prediction?
AUTHOR(S): Poroikov, V.; Akimov, D.; Shabelnikova, E.; Filimonov, D.
CORPORATE SOURCE: Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, Moscow, 119832, Russia
SOURCE: SAR and QSAR in Environmental Research (2001), 12(4), 327-344
CODEN: SQERED; ISSN: 1062-936X
PUBLISHER: Gordon & Breach Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **97322-87-7**, Troglitazone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug discovery through computer-aided prediction)
RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB Computer-aided prediction of the biol. activity spectra by the program PASS was applied to a set of 130 pharmaceuticals from the list of the Top 200 medicines. The known pharmacol. effects were found in the predicted activity spectra in 93.2% of cases. Addnl., the probability of some supplementary effects was also predicted to be significant, including **angiogenesis** inhibition, bone formation stimulation, possible use in cognition disorders treatment, multiple sclerosis treatment, etc. These predictions, if confirmed exptl., may become a cause for a new application of pharmaceuticals from the Top 200 list. Most of known side and toxic effects were also predicted by PASS. PASS predictions at earlier R & D stages may thus provide a basis for finding new "leads" among already launched drugs and may help direct more attention to those particular effects of pharmaceuticals in clin. use which become apparent only in a small part of the population and require addnl. precautions.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:394831 CAPLUS

DOCUMENT NUMBER: 136:161068

TITLE: Response of experimental retinal neovascularization to thiazolidinediones

AUTHOR(S): Murata, Toshinori; Hata, Yasuaki; Ishibashi, Tatsuro; Kim, Sarah; Hsueh, Willa A.; Law, Ronald E.; Hinton, David R.

CORPORATE SOURCE: Department of Ophthalmology, Keck Sch. Med., University of Southern California, Los Angeles, CA, USA

SOURCE: Archives of Ophthalmology (Chicago, IL, United States) (2001), 119(5), 709-717
CODEN: AROPAW; ISSN: 0003-9950

PUBLISHER: American Medical Association

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **97322-87-7**, Troglitazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(response of retinal neovascularization to thiazolidinediones)

RN 97322-87-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB To det. the effect of thiazolidinediones (TZDs) on exptl. retinal neovascularization. The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 .mu.mol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was detd. in response to vascular endothelial growth factor (VEGF). In vivo studies were performed using the oxygen-induced ischemia model of retinal neovascularization. Neonatal mice were treated with intravitreous injection of 0.5 .mu.L of troglitazone (100 .mu.mol/L) or rosiglitazone maleate (100 .mu.mol/L), or vehicle, and retinal neovascularization was assayed qual. and quant. by angiog. and histol. examn. Expression of the TZD receptor, peroxisome proliferator-activated receptor .gamma., was confirmed in RECs by Western immunoblotting. Rosiglitazone and troglitazone inhibited VEGF-induced migration, proliferation, and tube formation by RECs in vitro beginning at 10 .mu.mol/L. Rosiglitazone and troglitazone inhibited phosphorylation of extracellular signal-regulated mitogen-activated protein kinase 1 in RECs. Intravitreous injection of rosiglitazone or troglitazone inhibited development of retinal neovascularization but did not significantly inhibit VEGF overexpression in the ganglion cell layer of the ischemic retina. The TZDs inhibit exptl. retinal neovascularization with an effect that is primarily downstream of VEGF expression. The TZDs are widely prescribed and should be evaluated for their potential to inhibit the progression of diabetic retinopathy.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:337887 CAPLUS

DOCUMENT NUMBER: 135:132695

TITLE: Feedback control of arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-.DELTA.12,14-prostaglandin J2

AUTHOR(S): Tsubouchi, Yasunori; Kawahito, Yutaka; Kohno, Masataka; Inoue, Ken-ichiro; Hla, Timothy; Sano, Hajime

CORPORATE SOURCE: First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan

SOURCE: Biochemical and Biophysical Research Communications (2001), 283(4), 750-755
CODEN: BBRCA9; ISSN: 0006-291X

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(feedback control of arachidonate cascade in human rheumatoid synoviocytes by 15-deoxy-.DELTA.12,14-prostaglandin J2)

RN 97322-87-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB Rheumatoid arthritis (RA) is a chronic polyarticular joint disease assocd. with massive synovial proliferation, inflammation, and **angiogenesis**. PPAR-.gamma. ligands, both 15-deoxy-.DELTA.12,14-prostaglandin J2 (15d- PGJ2) and troglitazone (TRO), can inhibit the growth of RA synoviocytes in vitro, and suppress the chronic inflammation of adjuvant-induced arthritis in rats, but the potency of 15d-PGJ2 is higher than TRO. Prostaglandin (PG) E2 plays important roles in joint erosion and synovial inflammation. In the present study, 15d-PGJ2, but not TRO and other prostanoids, suppressed interleukin (IL)-1.beta.-induced PGE2 synthesis in rheumatoid synovial fibroblasts (RSFs) through the inhibition of cyclooxygenase (COX-2) and cytosolic phospholipase A2 (cPLA2) expression. Furthermore, the inhibition was not affected by pretreatment with anti-PPAR-.gamma. antibody. It means that this anti-inflammatory effect of 15d-PGJ2 for PG synthesis may be independent of PPAR-.gamma. and 15d-PGJ2 is a key regulator of neg. feedback of the arachidonate cascade on the COX pathway. These findings provide new insight into the feedback mechanism of the arachidonate cascade. (c) 2001 Academic Press.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:259756 CAPLUS

DOCUMENT NUMBER: 134:361740

TITLE: Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes

AUTHOR(S): Asano, A.; Irie, Y.; Saito, M.

CORPORATE SOURCE: Graduate School of Veterinary Medicine, Department of Disease Control, Hokkaido University, Sapporo, 060-0818, Japan

SOURCE: Molecular and Cellular Endocrinology (2001), 174(1-2), 71-76
CODEN: MCEND6; ISSN: 0303-7207

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(PPAR.gamma. agonist; isoform-specific regulation of VEGF family mRNA expression in cultured mouse brown adipocytes)

RN 97322-87-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB The authors have shown that brown adipose tissue (BAT), a thermogenic organ in mammals, expresses high levels of vascular endothelial growth factor (VEGF) mRNA in response to exposure to cold, which may contribute to **angiogenesis** assocd. with cold-induced hyperplasia of this tissue. In the present study, the authors examd. mRNA expression of not only VEGF, but also VEGF-B and VEGF-C, recently cloned VEGF isoforms, in

vitro using immortal brown adipocytes (HB2) isolated from mouse BAT. HB2 preadipocytes expressed detectable levels of VEGF, VEGF-B and VEGF-C mRNA, but a low level of VEGF. After HB2 cells differentiated into adipocytes, the VEGF mRNA level increased without a noticeable change in the VEGF-B and VEGF-C mRNA levels. When HB2 cells were stimulated by norepinephrine, the VEGF mRNA level increased without a change in that of VEGF-B, while the VEGF-C mRNA level decreased. A marked redn. of VEGF-C mRNA expression was also found when HB2 cells were treated with agonists of peroxisome proliferator-activated receptor .gamma. (PPAR.gamma., troglitazone), retinoic acid receptor (RAR, all-trans retinoic acid) and retinoid X receptor (RXR, 9-cis retinoic acid). These results suggest a specific adrenergic mechanism for up-regulation of VEGF expression different from those for other VEGF isoforms, and thereby the major contribution of VEGF to the cold-induced **angiogenesis** in BAT. In addn., the agonists of PPAR.gamma., RAR and RXR are suggested to be inhibitory to **angiogenesis** through the redn. of VEGF-C prodn.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:809642 CAPLUS
DOCUMENT NUMBER: 134:95235
TITLE: Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy
AUTHOR(S): Izuishi, Kunihiko; Kato, Kazuyoshi; Ogura, Tsutomu; Kinoshita, Taira; Esumi, Hiroyasu
CORPORATE SOURCE: Investigative Treatment Division, National Cancer Center Research Institute, National Cancer Center Hospital East, Chiba, 277-8577, Japan
SOURCE: Cancer Research (2000), 60(21), 6201-6207
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(tolerance of tumor cells to nutrient deprivation response to)

RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB It was hypothesized that the tolerance to nutrient deprivation as well as **angiogenesis** might be an important factor for tumor progression under hypovascular conditions. When normal human fibroblasts were subjected to extreme nutrient starvation by culturing in a medium without serum, glucose, and amino acids, the cells died within 24 h. When liver cancer cell lines HepG2, Hep3B, HLE, and HuH-7 were tested, cell death occurred within 36 h. In contrast, four of six pancreas cancer cell lines (PANC-1, AsPC-1, BxPC-1, and KP-3) survived for markedly longer periods; >50% of the cells survived, even after starvation for 48 h. Of three

gastric cancer cell lines (MKN28, MKN45, and MKN74), only the most poorly differentiated (MKN45) cells survived >36 h. More than 50% of the cells in colon cancer cell lines SW480, WiDr, and DLD-1 survived >36 h, and the most undifferentiated (SW480) cell line survived longest. The possible involvement of protein kinase B (PKB)/Akt expression in the survival of various cell lines under nutrient starvation conditions was examd. High expression of PKB/Akt was assocd. with tolerance for nutrient starvation. When Akt antisense RNA expression vectors were introduced into PANC-1 cells, the tolerance was partially but significantly diminished by vectors for Akt1 and Akt2 but not Akt3. Because elimination of the tolerance might serve as a new strategy for cancer therapy, some compds. were tested for this purpose, and troglitazone, an insulin sensitizer, as well as LY294002, a phosphatidylinositol 3-kinase inhibitor, were found to kill PANC-1 cells only under conditions of nutrient starvation.

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:368081 CAPLUS
DOCUMENT NUMBER: 133:12750
TITLE: Method using a PPAR.gamma. ligand/agonist for inhibiting **angiogenesis** and treating tumor growth
INVENTOR(S): Gerritsen, Mary E.; Xin, Xiaohua E.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000030628	A2	20000602	WO 1999-US27612	19991118
WO 2000030628	A3	20011011		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143953	A2	20011017	EP 1999-960538	19991118
EP 1143953	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001036955	A1	20011101	US 2001-865859	20010525

PRIORITY APPLN. INFO.:
US 1998-109328P P 19981120
US 1999-116530P P 19990120
US 1999-443010 B1 19991117
WO 1999-US27612 W 19991118

OTHER SOURCE(S): MARPAT 133:12750

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PPAR.gamma. ligand/agonist for inhibiting **angiogenesis** and treating tumor growth)

RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-

2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB **Angiogenesis** is inhibited and the growth of tumors is treated by administering an effective amt. of a PPAR.gamma. ligand/agonist, optionally with an RXR receptor ligand.

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:320014 CAPLUS
DOCUMENT NUMBER: 133:99344
TITLE: Peroxisome Proliferator-Activated Receptor-.gamma. Agonists Increase Vascular Endothelial Growth Factor Expression in Human Vascular Smooth Muscle Cells
AUTHOR(S): Yamakawa, Kenjiro; Hosoi, Masayuki; Koyama, Hidenori; Tanaka, Shinji; Fukumoto, Shinya; Morii, Hirotoshi; Nishizawa, Yoshiki
CORPORATE SOURCE: Second Department of Internal Medicine, Osaka City University Medical School, Osaka, 545-8586, Japan
SOURCE: Biochemical and Biophysical Research Communications (2000), 271(3), 571-574
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peroxisome proliferator-activated receptor-.gamma. agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells)
RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB Vascular endothelial growth factor (VEGF), expressed in a variety of mesenchymal cells including vascular smooth muscle cells (VSMC), is a potent mitogen for endothelial cells, and is used clin. applied for ischemic disease of peripheral vessels. To det. whether peroxisome proliferator-activated receptor .gamma. (PPAR.gamma.) regulates VEGF prodn. in VSMC, we examd. VEGF secretion from VSMC treated with PPAR agonists. Troglitazone increased VEGF secretion in a time- and

dose-dependent manner (261.+-.35% with 25 mM of troglitazone for 24 h), and also increased levels of VEGF mRNA. VEGF secretion was also increased by other PPAR.gamma. agonists, pioglitazone, LY171883, and 15d-PGJ2 (224.+-.17.1%, 247.+-.36.8% and 171.+-.7.8%, resp.), but not the PPAR.gamma. agonists bezafibrate and Wy14643 (85.2.+-.1.5%, 94.6.+-.3.2, resp.). Our findings suggest that thiazolidinediones might be useful for the therapeutic **angiogenesis** for ischemic artery disease. (c) 2000 Academic Press.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:15004 CAPLUS
DOCUMENT NUMBER: 132:73666
TITLE: Ophthalmic uses of PPAR-.gamma. agonists and antagonists
INVENTOR(S): Pershadsingh, Harrihar A.; Levy, Daniel E.
PATENT ASSIGNEE(S): Photogenesis, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000194	A1	20000106	WO 1999-US14262	19990625
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9947134	A1	20000117	AU 1999-47134	19990625
US 6316465	B1	20011113	US 1999-342381	19990628

PRIORITY APPLN. INFO.:
US 1998-90937P P 19980627
US 1998-90937 P 19980627
WO 1999-US14262 W 19990625

OTHER SOURCE(S): MARPAT 132:73666

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic uses of PPAR-.gamma. agonists and antagonists)

RN 97322-87-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB Methods are disclosed for treating diseases of ocular tissues expressing the nuclear receptor PPAR-.gamma., by inhibiting the inflammatory response, the neovascularization and **angiogenesis**, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amt. of a compd. that modifies the activity of PPAR-.gamma., or a pharmaceutically acceptable salt or solvate thereof. Novel compds. and methods for their synthesis are provided.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:373898 CAPLUS

DOCUMENT NUMBER: 131:183259

TITLE: Angiogenic effect of lipid hydroperoxide on bovine aortic endothelial cells

AUTHOR(S): Yamada, Yasuyo; Nakanishi-Ueda, Takako; Yasuda, Masako; Armstrong, Donald; Yamamoto, Yorihiro; Yamamoto, Toshinori; Yasuhara, Hajime

CORPORATE SOURCE: Department of Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan

SOURCE: Journal of Clinical Biochemistry and Nutrition (1998), 25(3), 121-130
CODEN: JCBNER; ISSN: 0912-0009

PUBLISHER: Institute of Applied Biochemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **97322-87-7**, Troglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(angiogenic effect of lipid hydroperoxide on bovine aortic endothelial cells)

RN 97322-87-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB To elucidate further the mechanism of lipid hydroperoxide (LHP) induced neovascularization, the authors detd. the effect of linoleic acid hydroperoxide (18:2-OOH) on bovine aortic endothelial cells (BAEC) in terms of cell proliferation, migration, and tube formation. The influence of some antioxidants on these systems were also investigated. The concn. of basic fibroblast growth factor (bFGF) in the culture medium was detd. by an immunoassay. Exposure to 10-7 M 18:2-OOH increased BAEC proliferation, migration, and tube formation by 117, 167, and 181%, resp., as compared with control values. The concn. of bFGF in the culture medium was increased 3-fold by 10-7 M 18:2-OOH exposure for 3 h, compared with that of controls (5.1 vs. 1.7 pg/mg protein). BAEC migration induced by 10-7 M 18:2-OOH was inhibited by 10-7 M bucillamine, which contains two sulfhydryl groups; by 10-7 M troglitazone, which structurally similar to .alpha.-tocopherol; and by 10-7 M EPC-K1, an .alpha.-tocopherol and ascorbic acid conjugate. Antioxidants showed marginal effects on proliferation. The de novo synthesis of bFGF after the 18:2-OOH stimulus

for 3 h was reduced from 5.1 pg/mg protein to 2.0 pg/mg protein by treatment with bucillamine. Apparently, 18:2-OOH induced BAEC growth is partly related to bFGF release or synthesis.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT